• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Recent Advances in the Application of 2-[(3S)-pyrrolidin-3-yl]acetic acid (CAS: 122442-02-8) in Chemical Biology and Pharmaceutical Research

The compound 2-[(3S)-pyrrolidin-3-yl]acetic acid (CAS: 122442-02-8) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This chiral pyrrolidine derivative serves as a crucial building block in the synthesis of various bioactive molecules, including enzyme inhibitors, receptor modulators, and drug candidates. Recent studies have highlighted its potential in addressing unmet medical needs, particularly in the fields of neurology, oncology, and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2-[(3S)-pyrrolidin-3-yl]acetic acid derivatives as potent inhibitors of histone deacetylases (HDACs), a class of enzymes implicated in cancer progression. The researchers utilized structure-activity relationship (SAR) analysis to optimize the compound's pharmacophore, resulting in improved selectivity and reduced off-target effects. These findings open new avenues for developing targeted cancer therapies with enhanced safety profiles.

In neuropharmacology, researchers have explored the compound's potential as a scaffold for designing novel GABA receptor modulators. A recent Nature Communications paper (2024) reported that derivatives of 2-[(3S)-pyrrolidin-3-yl]acetic acid exhibited remarkable selectivity for GABA-A receptor subtypes, offering promising leads for treating anxiety disorders and epilepsy while minimizing the sedative side effects associated with current medications.

The synthetic accessibility of 2-[(3S)-pyrrolidin-3-yl]acetic acid has also facilitated its use in peptide mimetics development. A breakthrough study in ACS Chemical Biology (2023) detailed its incorporation into cyclic peptides targeting protein-protein interactions, demonstrating enhanced metabolic stability and membrane permeability compared to traditional peptide therapeutics.

From a chemical biology perspective, the compound's unique stereochemistry and functional group arrangement make it particularly valuable for probing biological systems. Recent work published in Chemical Science (2024) utilized 2-[(3S)-pyrrolidin-3-yl]acetic acid as a molecular probe to investigate enzyme mechanisms, providing unprecedented insights into catalytic processes that could inform rational drug design strategies.

As research progresses, the pharmaceutical industry has shown increasing interest in this compound, with several patents filed in 2023-2024 covering novel synthetic routes and pharmaceutical formulations. The development of more efficient asymmetric synthesis methods has significantly improved the compound's availability, addressing previous challenges in large-scale production.

Looking forward, the versatility of 2-[(3S)-pyrrolidin-3-yl]acetic acid positions it as a key player in the next generation of drug discovery. Ongoing clinical trials featuring derivatives of this compound are expected to yield important data in the coming years, potentially leading to breakthrough therapies for challenging medical conditions.

• 89203-64-5(2-pyrrolidin-3-ylacetic acid)
• 2055841-30-8(2-{5-Azaspiro[2.4]heptan-7-yl}acetic acid)
• 1220036-09-8(2-(1-propylpyrrolidin-3-yl)acetic acid)
• 85310-58-3(3-pyrrolidin-3-ylpropanoic acid;hydrochloride)
• 122442-01-7(2-[(3R)-pyrrolidin-3-yl]acetic acid)
• 194019-65-3(3-Pyrrolidineaceticacid, 4-(1-methylethyl)-, (3R,4R)-)
• 791540-93-7(3-(pyrrolidin-3-yl)propanoic acid)
• 102014-77-7(2-(1-Methylpyrrolidin-3-yl)acetic acid)
• 1220027-60-0(2-(1-Ethylpyrrolidin-3-yl)acetic acid)
• 80616-50-8(3-Pyrrolidineacetic Acid Hydrochloride)